Oleylamine-carbonyl-valinol inhibits auto-phosphorylation activity of native and T315I mutated Bcr-Abl, and exhibits selectivity towards oncogenic Bcr-Abl in SupB15 ALL cell lines by Najajreh, Yousef et al.
Oleylamine-carbonyl-valinol inhibits auto-phosphorylation
activity of native and T315I mutated Bcr-Abl, and exhibits
selectivity towards oncogenic Bcr-Abl in SupB15 ALL cell lines
Yousef Najajreh • Hazem Khamaisie •
Nili Ruimi • Soliman Khatib • Joshua Katzhendler •
Martin Ruthardt • Jamal Mahajna
Received: 18 August 2012 / Accepted: 19 November 2012 / Published online: 5 December 2012
 Springer Science+Business Media Dordrecht 2012
Abstract Chronic myeloid leukemia (CML) is character-
ized by the presence of p210Bcr-Abl which exhibits an
abnormal kinase activity. Selective Abl kinase inhibitors
have been successfully established for the treatment of CML.
Despite high rates of clinical response, CML patients can
develop resistance against these kinase inhibitors mainly due
to point mutations within the Abl protein kinase domain.
Previously, we have identified oleic acid as the active com-
ponent in the mushroom Daedalea gibbosa that inhibited the
kinase activity of Bcr-Abl. Here, we report that the oleyl
amine derivatives, S-1-(1-Hydroxymethyl-2-methyl-pro-
pyl)-3-octadec-9-enyl-urea [oleylaminocarbonyl-L-N-
valinol,oroleylaminocarbonyl-S-2-isopropyl-N-ethanola-
mine,
oleylamine-carbonyl-L-valinol] (cpd 6) and R-1-(1-Hydro-
xymethyl-2-methyl-propyl)-3-octadec-9-enyl-urea [oleyla-
mineocarbonyl-D-N-valinol, oleylaminocarbonyl-R-2-iso-
propyl-N-ethanolamine, or oleylamine-carbonyl-D-valinol]
(cpd 7), inhibited the activity of the native and T315I
mutated Bcr-Abl. Furthermore, cpd 6 and 7 exhibited higher
activity towards the oncogenic Bcr-Abl in comparison to
native c-Abl in SupB15 Ph-positive ALL cell line.
Keywords Oleylamine  L-/D-Valinol  Anti-tumor
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Introduction
CML is a clonal myeloproliferative disorder of the hema-
topoietic stem cells and accounts for 15 % of leukemias in
adults [1, 2]. The translocation-related (9;22)-protein
product is the Bcr-Abl fusion protein, which displays a
constitutive tyrosine kinase activity, leading to the induc-
tion of aberrant proliferation and neoplastic transformation
by constitutive activation of target signaling pathways. The
Bcr-Abl induced phenotype in hematopoietic cells is
characterized by an increased proliferation as well as by a
reduced susceptibility to a variety of pro-apoptotic stimuli,
including growth factor deprivation [3].
Imatinib (Gleevec), a selective inhibitor of Abl kinase is
approved for the treatment of chronic phase CML (CP) and
is included in most clinical trials for the treatment of
Philadelphia-Chromosome positive (Ph?) acute lymphatic
leukemia (ALL) [4–6]. Unfortunately, the clinical efficacy
of the treatment with Imatinib continuously decreases with
the advancement of the disease. Blast crisis CML or Ph?
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ALL patients benefit from the treatment with tyrosine
kinase inhibitors only temporarily or not at all [7].
Acquired resistance is mostly due to the acquisition of
point mutations in Bcr-Abl by either reducing the affinity
of the kinase domain for this ATP-competitor, or stabiliz-
ing the active conformation of the Abl kinase domain.
Second generation inhibitors of Abl kinase activity
consists of compounds that can overcome Imatinib resis-
tance. Nilotinib (Tasigna) is a novel ATP-competitive and
is effective against a variety of cell lines expressing I-
matinib-resistant Abl mutants, Dasatinib (Sprycel) is a dual
Src/Abl kinase inhibitor that inhibits kinase activity of 14
out of 15 Imatinib resistant Abl mutants [8].
The major therapeutic challenge in Ph? leukemia
remains the ‘‘gatekeeper’’ mutation, T315I, which confers a
global resistance against nearly all molecular therapy
approaches targeting Bcr-Abl, such as ATP-competition,
oligomerization inhibition or allosteric inhibition [9, 10].
Recently, Ponatinib, a multi-targeted tyrosine-kinase
inhibitor, that is also effective against native Bcr-Abl and
other Bcr-Abl kinase mutations, including T315I mutation,
was approved by the FDA for the treatment of CML [11–13].
Previously, we identified a mycelium organic extract from
the medicinal mushroom Daedalea gibbosa with selective
anti-proliferating and apoptosis-inducing activities against
the CML-derived K562 cells [14]. In addition, we identified
an active fraction capable of directly inhibiting the kinase
activity of Abl, as well as the auto-phosphorylation activity
of native Bcr-Abl and the mutated forms, including the
T315I mutation. The active fraction of D. gibbosa also
inhibits the clonigenicity of native Bcr-Abl and its mutants
when expressed in BaF3 cells [15]. Structure elucidation of
the active moiety revealed that oleic acid is responsible for
the Bcr-Abl inhibition activity in the D. gibbosa extract [16].
In this study we evaluated the activity of two novel oleyl
amine derivatives, Oleylaminocarbonyl D/L-valinol, and
found that both are active in inhibiting cellular auto-
phosphorylation of native and T315I mutated Bcr-Abl.
Materials and methods
Chemicals
Oleyl amine 99 % was purchased from GL. Biochem China,
dicyclohexylcarbodiimide, N-hydroxysuucinimide, sodium
sulfate (Na2SO4), dimethylformamimde, dichloromethane,
ethyl acetate, triethylamine, methanol (MeOH), ethanol
(EtOH), hexane, chloroform (CHCl3) and pyridine were pur-
chased from ACROS Chemicals Ltd (Israel). (NaOH), tetra-
hydrofuran, dioxane and sulfuric acid (H2SO4) were purchased
from Sigma-Aldrich Chemicals Ltd (Israel). Chemicals were
used without further purification. Silica gel (Silica gel 60
(0.040–0.063 mm), thin layer chromatography (TLC Silica gel
60 F254) sheets were all purchased from Merck Ltd. Deuterated
solvents for NMR: D2O, CDCl3, DMSO-d6 was purchased
from ACROS Chemicals Ltd (Israel). 1H-NMR and 13C-NMR
data were collected using Varian Unity Inova 500 MHz spec-
trometer equipped with a 5-mm switchable tube and data were
processed using the VNMR software.
Cell lines and cell cultures
Ba/F3 cells expressing Bcr-Abl were previously described
[15]. Ba/F3 expressing JAK2 V617F were received from
Prof. Shai Izraeli (Functional Genomics and Leukemia
Research Pediatric Hemato-Oncology and Cancer Research
Center, Sheba Medical Center, Israel) and were grown in
RPMI 1640 with 2 mM L-glutamine supplemented with
10 % fetal bovine serum. Penicillin at 100 U/ml and
streptomycin at 100 lg/ml were added to the culture
media. All cell lines were grown at 37 C in a humidified
atmosphere with 5 % CO2.
Cellular auto-phosphorylation of Bcr-Abl
Ba/F3 cells expressing the native Bcr-Abl protein (4 9 105
cells/ml) were treated with oleic acid derivatives, Abl
kinase inhibitors, and DMSO for 1 h. Cells were collected,
washed once with cold PBS, and lysed as indicated before.
Cell lysate supernatants (40 lg protein) were resolved on
8 % SDS–polyacrylamide gel electrophoresis, transferred
to nitrocellulose membranes, and analyzed by immune-
blotting with Anti-phospho-c-Abl(Tyr245) polyclonal
antibody (Cell Signaling Technology, USA). The phos-
phorylated level of Bcr-Abl protein was compared to total
Abl, which was detected using Anti-c-Abl monoclonal
antibody (Santa Cruz Biotechnology, USA).
Trypan blue exclusion assay
Ba/F3 cells were plated (4 9 105cells/well) in six-well
plates, with each well containing 3 ml medium. After 24 h,
cells were treated with the appropriate agents. Solvent-
treated samples were incubated with 1 % DMSO. Seventy-
two hours later, the cells were collected, stained with 0.4 %
trypan blue solution (1:1), and counted using a hemacy-
tometer to determine IC50 values.
Colony-forming assay
A colony-forming assay was performed as previously
described [15]. Briefly, cells (1 9 104) in 1 ml RPMI/10 %
FBS medium were diluted in 1 ml of 0.6 % agar to give a
final agar concentration of 0.3 % agar. The cell-agar mix-
ture was poured on top of a hardened agar base in wells of
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12-well plates and allowed to solidify. Once the top layer
solidified, 1 ml of medium containing different treatments
was placed on top to keep the agar moist. The cells were
grown at 37 C in a 5 % CO2 humidified atmosphere until
colonies were visible (2–3 weeks). The plates were stained
for 4 h with 5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide, and the dye was extracted
with 1 ml solubilization buffer (20 % sodium dodecyl
sulfate [SDS], 50 % N,N-dimethyl-formamide, 25 mM
HCL) for 24 h. The optical density was measured at
570 nm wavelength with a reference wavelength of
630 nm.
Cell proliferation (XTT) assay
The XTT method was used to evaluate the cytotoxicity of
the oleic acid derivatives. Bcr-Abl positive cell lines
(1.5 9 104) were maintained in the appropriate media
using 96-well plates for 24 h, and then treated for an
additional 72 h with the appropriate agents. A total of 50 ll
of XTT solution were added to each well and incubated for
three hours at 37 C. The optical density was measured by
a multi-well plate spectrophotometer at 405 nm. The con-
centrations inhibiting cell proliferation by 50 % (IC50s)
were calculated.
Synthesis of oleylamino-L/D-N-Valinol
Oleyl amine (0.8 g, 3 mmol) was dissolved in 10 ml dried
pyridine. While stirred at room temperature (0.486 g,
3 mmol) carbonyldiimidazole were added. The mixture
was stirred for 48 h. Reaction progress was monitored by
TLC (100 % ethyl acetatae and I2 as developer). When the
starting material disappeared, one equivalent (3 mmol) of
the desired aminoethanol L-Valinol or D-valinol was added
and the mixture was stirred for 2 days at room temperature.
Reaction progress was followed by TLC [100 % Ethyl
acetate, I2]. After the reaction termination, as was followed
by TLC [100 % EtAc], the solvent was removed under
reduced pressure and the resultant was purified employing
column chromatography (100 % CHCl3). The fractions
containing the desired product were pooled, and volatiles
were evaporated under reduced pressure.
Oleylaminocarbonyl-L-N-Valinol;
[Oleylaminocarbonyl-S-2-isopropyl-N-ethanolamine]
(cpd 6):
Yield = (1 g, 84.4 %), TLC (100 % CHCl3; I2).
1H-NMR (CDCl3, dppm): 0.87(t, 3H), 0.94(q, 6H),
1.28(m, 2H), 1.81(m, 2H), 2.01(m, 5H), 3.15(t, 2H), 3.51(m,
1H), 3.71(d, 2H), 5.34(dd, 2H).
13C-NMR(CDCl3, d ppm): 14.32, 18.98, 19.76,
22.90,27.15, 27.43,29.73, 29.94, 30.38, 32.13, 41.07,58.51,
65.43,130.10, 159.62.
Oleylaminocarbonyl-D-N-
Valinol;[Oleylaminocarbonyl-R-2-isopropyl-N-
ethanolamine] (cpd 7)
Yield = (0.830 g, 70.8 %). TLC (100 % CHCl3; I2).
1H-NMR(CDCl3, dppm): 0.87(t, 3H), 0.94(q, 6H),
1.28(m, 2H), 1.81(m, 2H), 2.01(m, 5H), 3.15(t, 2H),
3.51(m, 1H), 3.71(d, 2H), 5.34(dd, 2H).
13C-NMR (CDCl3, dppm):14.32,18.98,19.76,22.90,27.15,
27.43,29.73,29.94,30.38,32.13,41.07,58.51,65.43,130.10,
159.62.
Molecular docking
The crystal structures of Abl and JAK2 were retrieved from
the Protein Data Bank (PDB) [17, 18] and docking to the
two proteins was performed by the ADT (AutoDock Tools)
program, an accessory program that allows the user to
interact with AutoDock4.2 from a graphic user interface.
Water molecules and other ligands were removed from the
protein PDB file. Polar hydrogen atoms were added and
Kollman united atomic charges assigned. The solvation
parameters were added by the Addsol program (part of the
ADT program) and the grid points were set to 80, 80, 80,
the spacing value equivalent to 0.375 and the grid center to
16.32, 8.79, -35.89 for Bcr-Abl and 70, 70, 76, the spacing
value equivalent to 0.375 and the grid center to -0.87,
2.66, 24.403 for JAK2. The structures of cpd 6 and cpd 7
were prepared using ‘‘CS ChemdrawPro’’ and ‘‘CS
ChemBats3DPro’’ and optimized to their minimum energy.
Ligand-docking was carried out with the AutoDock 4.2
Genetic Algorithm (GA) [19, 20].
Results
Previously, we identified oleic acid as the active compo-
nent in the mushroom D. Gibbosa that inhibited the auto-
phosphorylation and kinase activity of native and mutated
Bcr-Abl, including the ‘‘gatekeeper’’ T315I mutation,
which confers absolute resistance to Imatinib [14–16].
In this study, we examined the activity of a number of
oleyl amine derivatives on Bcr-Abl auto-phosphorylation
(data not shown). Figure 1 shows the synthesis and the
structure of the two oleyl amine derivatives, Oleylamino-
carbonyl-L-N-valinol (cpd 6) and Oleylaminocarbonyl-
D-N-valinol (cpd 7) that were active in inhibiting Bcr-Abl
auto-phosphorylation.
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Oleylaminocarbonyl-D/L-N-valinol inhibits native
and mutated Bcr-Abl cellular auto-phosphorylation
in Ba/F3 cells
The ability of the two oleyl amine derivatives, Oleylami-
nocarbonyl-L-N-valinol (cpd 6) and Oleylaminocarbonyl-
D-N-valinol (cpd 7), to affect cellular Bcr-Abl auto-phos-
phorylation was monitored using immune-blotting.
Figure 2 shows that both derivatives inhibited the auto-
phosphorylation activity of the native Bcr-Abl protein
(Fig. 2a). In contrast to Imatinib, an ATP competitor, and
GNF-2, an Abl allosteric inhibitor [10], the two derivatives
also inhibited the auto-phosphorylation of the T315I
mutated Bcr-Abl in a comparable potency to that exhibited
against the native form (Fig. 2a). Furthermore, both oleyl
amine derivatives were active in inhibiting the phosphor-
ylation of STAT5a, a downstream Bcr-Abl target, from
native and T315I mutated cells, in a comparable potency
(Fig. 2a). Similarly, the two oleyl amine derivatives were
also active in inhibiting the auto-phosphorylation of other
Bcr-Abl mutations, such as the ATP binding loop mutants,
Y253F (Fig. 2b). Interestingly, the activity of Oleylami-
nocarbonyl D/L-N-valinol against pBcr-Abl was much
profound compared to their activity against pSTAT5a.
Furthermore, cpd 6 (Oleylaminocarbonyl-L-N-Valinol)
exhibited an increased potency compared to cpd 7 (Ole-
ylaminocarbonyl-D-N-Valinol).
Effect of Oleylaminocarbonyl-D/L-N-valinol on
Bcr-Abl cellular auto-phosphorylation in Ph? patient-
derived cell lines
Next, we tested the ability of the two Oleylaminocarbonyl
D/L-N-valinol compounds to affect Bcr-Abl auto-phos-
phorylation using Ph? patient-derived cell lines, such as
K562, MEG-01, BV173, and SupB15. Results shown in
Fig. 3 illustrated that derivative Oleylaminocarbonyl-L-N-
Valinol (cpd 6) and derivative Oleylaminocarbonyl-D-N-
Valinol (cpd 7) exhibited variable activity in inhibiting Abl
phospho-tyrosine in the different patient-derived cell lines,
as measured by pTyr Abl ELISA assay (Fig. 3a, b) [15].
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Fig. 1 Synthesis and chemical
structure of oleylaminocarbonyl
L-N-valinol [L-1-(1-
Hydroxymethyl-2-methyl-
propyl)-3-octadec-9-enyl-urea
(cpd 6) and oleylaminocarbonyl
D-N-valinol [D-1-(1-
Hydroxymethyl-2-methyl-
propyl)-3-octadec-9-enyl-urea]
(cpd 7) as outlined in Materials
and methods
1  2   10  50  10  30 100  10  30   100
D        I           GNF-2                        Cpd 6                          Cpd 7
Bcr-Abl
pBcr-Abl
pSTAT-5α
α - tubulin
Ba/F3 p185 Bcr-Abl Y253F 
(µM)
A
B
Fig. 2 Inhibition of pBcr-Abl and pSTAT5a in Ba/F3 cells carrying
p185 Bcr-Abl, p185 Bcr-Abl T315I (a) and p185 Bcr-Abl Y253F
(b) constructs by OleylaminocarbonylL-valinol (cpd 6) and Oleyla-
minocarbonyl D-N-valinol (cpd 7). Immunoblots of Bcr-Abl, Abl,
pBcr-Abl, pAbl and pSTAT5a in response to Oleylaminocarbonyl
D-valinol and Oleylaminocarbonyl L-N-valinol were monitored. a-
tubulin was used as loading control. D, DMSO, I, Imatinib at 1 lM,
and G, GNF-2 at 10 lM
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The two derivatives were effective in inhibiting Abl
phospho-tyrosine levels in Ph? megakaryoblastic MEG-01
cell lines (Fig. 3a). In contrast, they failed to inhibit Abl
phospho-tyrosine levels in K562 cell lines (Fig. 3a), and
showed only marginal activity in B-lineage precursor ALL
SupB15 and BV173 cell lines (Fig. 3b).
Next, we followed the effect of the two oleyl amine
derivatives on the levels of pBcr-Abl, pAbl and pSTAT5a in
the various Ph? patient-derived cell lines using
immunoassay. Our data illustrated that while Bcr-Abl was
expressed at comparable levels in the different Ph? cell
lines, the levels of the endogenous c-Abl varied significantly.
Levels of endogenous c-Abl were low in MEG-01 (Fig. 3d)
and Ba/F3 cells and significantly high in K562 (Fig. 3b) and
SupB15 (Fig. 3c). Figs. 3c–e summarize the obtained
results. Figure 3c shows that levels of pAbl and pBcr-Abl
from K562 (p210 Bcr-Abl CML) cell lines were significantly
inhibited in the presence of Imatinib (1 lM) and GNF-2
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D          I      GNF-2                   Cpd 6                    Cpd 7
1        2      10      50       10      30     100     10      30      100     (µM)
SupB15
A
B
C
D
E
Fig. 3 Inhibition of Bcr-Abl auto-phosphorylation from ph? patient-
derived cell lines. Levels of Abl pTyrosine in response to Oleylami-
nocarbonyl D-N-valinol (cpd 6) and Oleylaminocarbonyl L-N-valinol
(cpd 7) using K562 and MEG-01 (a) and ALL cell lines SupB15 and
BV-173 (b). Immunoblots of Bcr-Abl, Abl, pBcr-Abl, pAbl and
pSTAT5a in response to Oleylaminocarbonyl D-valinol and Oleyla-
minocarbonyl L-valinol were monitored in K562 (c), MEG-01 (d) and
SupB15 (e) patient-derived cell lines. a-tubulin was used as loading
control. D, DMSO and I, Imatinib
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(2 lM–50 lM). However, the two derivatives were not
effective in inhibiting neither pAbl nor pBcr-Abl (Fig. 3c).
Similarly, levels of pSTAT5a were only marginally affected
by the presence of the two derivatives at the highest con-
centration (100 lM). Treatment of MEG-01 cell lines (p210
Bcr-Abl AMKL) with the two compounds resulted in a sig-
nificant inhibition of pBcr-Abl and pSTAT5a (Fig. 3d). The
two derivatives were also active in inhibiting pBcr-Abl
levels in the SupB15 (p190 Bcr-Abl ALL) cell line (Fig. 3e).
Interestingly, cpd 6 (Oleylaminocarbonyl-L-N-Valinol)
exhibited a higher potency in inhibiting pBcr-Abl compared
to cpd 7 (Oleylaminocarbonyl-D-N-Valinol). In addition,
levels of pSTAT5a were also affected by both compounds,
with cpd 6 showing higher potency compared to cpd 7.
Interestingly, phosphorylation levels of endogenous c-Abl
were only marginally affected by the presence of both
derivatives in SupB15 cell lines (Fig. 3e).
Oleylaminocarbonyl D/L-N-valinol inhibits
phosphorylation of JAK2 V617F
Previously, we showed that GNF-2, an Abl allosteric
inhibitor, is moderately active in inhibiting auto-phos-
phorylation of V617F JAK2 kinase [24]. In this report, the
ability of the two oleic acid derivatives to inhibit auto-
phosphorylation of V617F JAK2 was monitored using Ba/
F3 expressing V617F JAK2 kinase. Results, presented in
Fig. 4, demonstrated that Imatinib (1 lM) was not active in
inhibiting JAK2 phosphorylation. In contrast, GNF-2 at
50 lM was effective in inhibiting JAK2 phosphorylation as
previously shown [24]. Similarly, the two oleic acid
derivatives (cpd 6 and cpd 7) significantly inhibited JAK2
phosphorylation at the highest concentration, and exhibited
a partial inhibition at 30 lM. In addition, level of JAK2
downstream targets, such as pSTAT5a, was also inhibited
by GNF-2 as well as by the two oleic acid derivatives,
though with somewhat reduced potency in comparison to
the observed effect on pJAK2 V617F.
Oleylaminocarbonyl D/L-N-valinol inhibits
clonigenicity of cells harboring activated Bcr-Abl
and JAK2 kinases
Anchorage-independent growth is one of the hallmarks of
transformation, which is considered the most accurate and
stringent in vitro assay for detecting malignant transfor-
mation of cells. Anchorage-independent growth, which
approximates tumorgenesis of cancer cells, measures the
proliferation and colony-formation of cancer cells in a
semi solid culture media. Ba/F3 cells carrying either the
native Bcr-Abl (p185), T315I mutated Bcr-Abl, and
activated (V617F) JAK2 were utilized to monitor cloni-
genicity in the presence of Oleylaminocarbonyl D/L-N-
valinol compounds. Results shown in Fig. 5 demonstrated
that Imatinib, Nilotinib, and GNF-2 were active in
inhibiting clonigenicity of Ba/F3 cells carrying the native
Bcr-Abl, but not cells carrying the T315I mutation or
activated JAK2. GNF-2 inhibited clonigenicity of cells
carrying native and T315I Bcr-Abl with IC50 of 0.8 and
26 lM, respectively (data not shown). Presence of Ole-
ylaminocarbonyl D-N-valinol and Oleylaminocarbonyl
L-N-valinol were only moderately effective in inhibiting
clonigenicity of Ba/F3 cells carrying the native Bcr-Abl,
the T315I mutated Bcr-Abl, and the activated JAK2
constructs, with IC50 values of 69, 60, and 37 lM,
respectively.
D   I  G 100 50 25 100 50 25 (µM)
Ba/F3 p185 Bcr-Abl
Ba/F3 p185 Bcr-Abl
T315I
Ba/F3 JAK2 F617V
Cpd 6                      Cpd 7Fig. 5 Clonogenicity of Ba/F3
cells carrying native Bcr-Abl,
T315I mutated Bcr-Abl, and
V617F mutated JAK2. Cells
grown on soft agar were treated
with 0.5 % DMSO (D), Imatinib
1 lM (I), GNF-2 2 lM (G), cpd
6, and cpd 7 (25–100 lM)
D   I 2 10 50 10 30 100 10 30 100 (µM)
GNF-2                Cpd 6                Cpd 7
JAK2
pJAK2
Ba/F3 JAK2 F617V
pSTAT5α
α-tubulin
Fig. 4 Inhibition of V617F JAK2 phosphorylation by Oleylamino-
carbonyl D/L-N-valinol compounds. Immunoblots of JAK2, pJAK2
and pSTAT5a in response to Oleylaminocarbonyl D-valinol and
Oleylaminocarbonyl L-N-valinol were monitored. a-tubulin was used
as loading control. D, DMSO and I, Imatinib
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Discussion
In an attempt to discover a new chemical entity that will be
effective in inhibiting the kinase activity of native and
T315I mutated Bcr-Abl, we identified an active organic
extract from the medicinal mushroom D. gibbosa [14], and
in a subsequent study we identified the active component as
oleic acid [16]. In the present study, we synthesized two
oleyl amine derivatives; oleylaminocarbonyl L-N-valinol
(cpd 6) and oleylaminocarbonyl D-N-valinol (cpd 7) and
evaluated their activity against native and mutated
Bcr-Abl.
The two oleylamine derivatives were active in inhibiting
the auto-phosphorylation of native, T315I, and Y253F
mutated Bcr-Abl. Moreover, both compounds inhibited the
phosphorylation of STAT5a, a well-known Bcr-Abl
downstream target. Interestingly, the Y253F mutated Bcr-
Abl was more sensitive to the activity of the two oleyl-
amine derivatives (Fig. 2b). Furthermore, the ability of the
two compounds to inhibit the phosphorylation of STAT5a
in Ba/F3 p185 Bcr-Abl Y253F cells was reduced in com-
parison to their ability to inhibit Bcr-Abl auto-phosphory-
lation in the same cells. Moreover, we noticed that the
L isomer of oleylaminocarbonyl-L-N-valinol (cpd 6)
exhibited enhanced activity in inhibiting Y253F Bcr-Abl
auto-phosphorylation in comparison to the D isomer
(cpd 7), arguing that the L isomer of Oleylaminocarbonyl-
D/L-N-valinol is somewhat more selective towards Y253F
mutated Bcr-Abl.
In addition, we evaluated the activity of the two oleic
acid derivatives against Bcr-Abl protein of different sizes
(p185 Vs. p210), and against Bcr-Abl expressed in differ-
ent cellular backgrounds. Our data illustrated that the two
oleyl amine derivatives exhibited activity against
p185Bcr-Abl produced in Ba/F3 p185Bcr-Abl cells and also in
SupB15, as well as against the major product of Ph?
translocation, p210Bcr-Abl protein, such as in MEG-01 cell
lines. However, the potency of the two derivatives seems to
be influenced by the cellular background. While the two
derivatives were potent in inhibiting p210Bcr-Abl in
MEG-01, they showed only a marginal activity against
p210Bcr-Abl in K562 cell line. The mechanism responsible
for such a cell-type specificity remains to be elucidated.
Moreover, our results illustrated that the different
Bcr-Abl positive cells exhibit different levels of the
endogenous Abl protein (c-Abl) expression. While SupB15
Fig. 6 Orientation of GNF-2, cpd 6, and cpd 7 within Bcr-Abl (A, C)
and JAK2 (B, D) at the myristoyl binding pocket. A and B show
docking of GNF-2 to Abl (a) and JAK2 (b). Docking of cpd 6 and
cpd 7 with Abl (c) and JAK2 (d) using autodock 4.2 program. The
various ligands are oriented to the hydrophobic zones of the enzymes
and interact with the hydrophobic myristoyl binding pocket in Abl.
The binding energy of the interaction with Abl was -3.22 and -3.70
for cpd 6 and cpd 7, respectively, and with JAK2 was -4.06 and -
3.11 for cpd 6 and cpd 7, respectively. The binding energy of the
interaction between GNF-2 with Abl was -6.78, and -6.58 with
JAK2
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expresses high levels of the endogenous c-Abl, a very
minimal amount of c-Abl was observed in MEG-01. Fur-
thermore, we observed that the two derivatives exhibited
different potency towards the Abl proteins, endogenous
c-Abl (myristoylated) and the oncogenic Bcr-Abl (non-
myristoylated). The two oleyl amine derivatives were much
more potent in inhibiting the non-myristoylated Bcr-Abl
compared to the myristoylated endogenous c-Abl. Our
findings are in agreement with an observation showing the
ability of GNF-2 to inhibit the kinase activity of Bcr-Abl
more potently than that of the myristoylated c-Abl by
binding to the myristate-binding pocket in the C-lobe of the
kinase domain [21]. Moreover, our findings are also in
agreement with observations made by Choi et al. 2009,
[21] and others, in which Brij-35, a non-ionic detergent
consists of a polyoxyethylene group attached to a 12-
carbon unsaturated moiety, commonly used in in vitro
kinase assay, is speculated to act as a competitor for the
binding to the myristate-binding pocket. Furthermore, our
findings argue for the potential development of oncogenic-
selective Abl inhibitors, similarly to the differential sensi-
tivity of the oncogenic EGFR towards Erlotinib and Gefi-
tinib compared to the wild-type EGFR receptor [22], and
also to the differential sensitivity of the recently FDA
approved vemurafenib (PL 9 4032) towards activated
BRAF V600E as compared to BRAF WT [23]. However,
the bases for such selectivity of the two oleyl amine
derivatives remain to be elucidated.
Although GNF-2 appears to be a selective Abl allosteric
inhibitor, and exhibits no detectable inhibitory activity
towards the closely related Src family of tyrosine kinases
[21], our current findings demonstrated that GNF-2 also
exhibited a significant inhibitory activity against native and
activated JAK2 (personnel communication). In this study,
our data illustrated (Fig. 4) that the two oleyl amine
derivatives were also active in inhibiting the phosphory-
lation of V617F JAK2, and its downstream target,
STAT5a, at a comparable potency as GNF-2.
As expected, the two oleyl amine derivatives were also
active in inhibiting clonigenicity of Ba/F3 cells harboring
Bcr-Abl or JAK2 constructs, as well as Ph? patient-
derived cell lines. Our data presented in Fig. 5a, demon-
strated that the L isomer (cpd 6) exhibited a comparable
activity against Ba/F3 cells carrying native and T315I
mutated Bcr-Abl, and with a slightly enhanced potency
against Ba/F3 cells carrying V617F mutated JAK2. In
contrast, the D isomer (cpd 7) exhibited a comparable
activity in inhibiting the clonigenicity of Ba/F3 cells har-
boring the mutated Bcr-Abl and JAK2 with reduced
potency towards cells harboring the native Bcr-Abl in
MEG-01 and K562 cells.
Although we have no experimental data showing the
mechanism of action of the two oleyl amine derivatives,
our docking experiments presented in Fig. 6 showed that a
potential interaction in the Abl protein is located in the
myristate-binding pocket (MBP), close to the region
occupied by GNF-2. Furthermore, our molecular docking
also argue that GNF-2, as well as the two oleyl amine
derivatives, also interact with a hydrophobic region within
the JAK2 protein, which resembles the myristate-binding
pocket within the Abl protein.
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